rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

ImageneBio, Inc.

IMA · Nasdaq

Health CareBiotechnologyNot moving yet

IMA stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 25.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$96K
Insider sales, 12 months
$35K
Officials’ trades on record
0
Institutions holding
36 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$10.1MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months2
Buyers · sellers1 · 1
WhoDidSharesTraded
Robert B. LallyPrincipal Accounting Officersold1,525at $5.3417 Jul 2026filed 20 Jul 2026
Robert B. LallyPrincipal Accounting Officersold1,671at $5.5016 Jul 2026filed 20 Jul 2026
Orbimed Advisors LlcDirectorbought336,60314 Apr 2026filed 16 Apr 2026
Orbimed Advisors LlcDirectorbought384,68914 Apr 2026filed 16 Apr 2026
David P. BonitaDirectorbought336,60314 Apr 2026filed 16 Apr 2026
David P. BonitaDirectorbought384,68914 Apr 2026filed 16 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders36+0 on the quarter
New · exited7 · 7
Reported value$37.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BVF INCunchanged · filed 14 Aug 20261,110,002$6.5M00.0%
Blue Owl Capital Holdings LPreduced · filed 11 Aug 2026917,692$5.4M-41,645−4.3%
ORBIMED ADVISORS LLCadded · filed 14 Aug 2026909,269$5.4M+530,713+140.2%
Cable Car Capital, LPadded · filed 14 Aug 2026781,599$4.6M+26,850+3.6%
Omega Fund Management, LLCunchanged · filed 14 Aug 2026455,361$2.7M00.0%
RTW INVESTMENTS, LPunchanged · filed 14 Aug 2026334,445$2.0M00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026320,518$1.9M-4,637−1.4%
Trails Edge Capital Partners, LPnew · filed 14 Aug 2026282,004$1.7M+282,004
BML Capital Management, LLCunchanged · filed 7 Aug 2026200,730$1.2M00.0%
Monashee Investment Management LLCnew · filed 13 Aug 2026192,344$1.1M+192,344
30 Sep 2025 – 30 Jun 2026
323640Sep 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Kristin Yarema Company insiderChief Executive Officer · last 14 Aug 20260 · 0
Yanina Grant-Huerta Company insiderChief Financial Officer · last 14 Aug 20260 · 0
Robert B. Lally Company insiderPrincipal Accounting Officer · last 17 Jul 20260 · 2
David P. Bonita Company insiderDirector · last 16 Jun 20266 · 0
Jonathan Jian Wang Company insiderDirector · last 16 Jun 20260 · 0
Joseph P. Slattery Company insiderDirector · last 16 Jun 20261 · 0
Otello Stampacchia Company insiderDirector · last 16 Jun 20261 · 0
ORBIMED ADVISORS LLC Company insiderDirector · last 14 Apr 20260 · 0
Orbimed Genesis Gp Llc Company insiderDirector · last 14 Apr 20262 · 0
Erin Butler Company insiderPrincipal Accounting Officer · last 30 Dec 20250 · 0
Stephen Hui Wang Company insiderDirector · last 18 Dec 20250 · 0
Jotin Marango Company insiderChief Financial Officer · last 28 Jul 20250 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-34.2%
Share count trendFY 2024 · to 28 Feb 20250.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$94.5M

Analyst forecasts

No analyst forecasts yet.